GP/1635 #1

I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date of Signature and Deposit: 11/8/01

Jan C. Bahn
Attorney of Record

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Martin G. Sirois, et al.
Serial No.:	09/945,131
Filed:	August 31, 2001
For:	LOCALIZED OLIGONUCLEOTIDE THERAPY FOR PREVENTING RESTENOSIS
Group Art Unit:	1635
Examiner:	--

Commissioner For Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. 1.98, enclosed herewith is a list of documents which the Applicants in the above-identified patent application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this patent application. As some of this information duplicates information presented in related case Serial No. 09/241,561, Applicants have not provided copies of the duplicated documents.

U.S. Patents

5,593,974; Rosenberg, et al.; January 14, 1997.

Foreign Patents

93/08845; PCT; May 13, 1993.

Other Documents

J. Abe, et al., "Suppression of neointimal smooth muscle cell accumulation *in vivo* by antisense CDC2 and CDK2 oligonucleotides in rat carotid artery," Biochemical and Biophysical Research Communications, 198(1):16-24 (1994).

S. Agrawal, et al., "Oligodeoxynucleoside phosphoramiddates and phosphorothioates as inhibitors of human immunodeficiency virus," Proc. Natl. Acad. Sci. USA 85:7079-7083 (1988).

S. Agrawal, et al., "Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues," Proc. Natl. Acad. Sci. USA 86:7790-7794 (1989).

S. Agrawal, et al., "Site-specific excision from RNA by Rnase H and mixed-phosphate-backbone oligodeoxynucleotides," Proc. Natl. Acad. Sci. USA 87:1401-1405 (1990).

S. Agrawal and J. Goodchild, "Oligodeoxynucleoside methylphosphonates: synthesis and enzymic degradation," Tetrahedron Letters 28(31):3539-3542 (1987).

R.K. Assoian, et al., "Cellular transformation by coordinated action of three peptide growth factors from human platelets," Nature 309:804-806 (1984).

W. Bannwarth, "166. Solid-phase synthesis of oligodeoxynucleotides containing phosphoramidate internucleotide linkages and their specific chemical cleavage," Helvetica Chimica Acta 71:1517-1527 (1984).

H.R. Baumgartner, "Platelet interaction with vascular structures," Thromb. Diath. Haemorrh. Suppl. 51:161-176 (1972).

M.R. Bennett, et al., "Inhibition of vascular smooth muscle cell proliferation *in vitro* and *in vivo* by c-myc antisense oligodeoxynucleotides," J. Clin. Invest. 93:820-828 (1994).

S. Biro, et al., "Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration," Proc. Natl. Acad. Sci. USA 90:654-658 (1993).

T.L. Burgess, et al., "The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth

muscle cells is caused by a nonantisense mechanism," Proc. Natl. Acad. Sci. USA 92:4051-4055 (1995).

A.W. Clowes and S.M. Schwartz, "Significance of quiescent smooth muscle migration in the injured rat carotid artery," Circulation Research 56(1):139-145 (1985).

A.W. Clowes, et al., "Kinetics of cellular proliferation after arterial injury. III. Endothelial and smooth muscle growth in chronically denuded vessels," Laboratory Investigation 54(3):295-303 (1986).

G. Cohen, et al., "Microbial isopenicillin N synthase genes: structure, function, diversity and evolution," Trends in Biotechnology 8:105-111 (1990).

R.M. Crooke, "*In vitro* toxicology and pharmacokinetics of antisense oligonucleotides," Anti-Cancer Design 6:609-646 (1991).

R. Cosstick and J.S. Vyle, "Solid phase synthesis of oligonucleotides containing 3'-thiothymidine," Tetrahedron Letters 30:4693-4696 (1989).

Y. Daaka and E. Wickstrom, "Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells," Oncogene Research 5:267-275 (1990).

M. Ebbecke, et al., "Antiproliferative effects of a c-myc antisense oligonucleotide on human arterial smooth muscle cells," Basic Res. Cardiol. 87:585-591 (1992).

E.R. Edelman, et al., "C-myc in vasculoproliferative disease," Circulation Research 76(2):176-182 (1995).

E.R. Edelman, "Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury," Proc. Natl. Acad. Sci. USA 87:3773-3777 (1990).

G.A.A. Ferns, et al., "Inhibition of neointimal smooth muscle accumulation after angioplasty by a antibody of PDGF," Science 253:1129-1132 (1991).

G. Anfossi, et al., "An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines," Proc. Natl. Acad. Sci. USA 86:3379-3383 (1989).

J. Goodchild, et al., "Inhibition of rabbit beta-globin synthesis by complementary oligonucleotides: identification of mRNA sites sensitive to inhibition," Archives of Biochemistry and Biophysics 263(2):401-409 (1988).

M.A. Guvakova, et al., "Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and

remove it from low affinity binding sites on extracellular matrix," The Journal of Biological Chemistry 270(6):2620-2627 (1995).

C.-H. Heldin, "Partial purification and characterization of platelet factors stimulating the multiplication of normal human glial cells," Experimental Cell Research 109:429-437 (1977).

J.T. Holt, et al., "An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation," Molecular and Cellular Biology 8(2):963-973 (1988).

D.L. Hwang, "Effects fo platelet-contained growth factors (PDGF, EFG, IGF-I, and TGF-beta) on DNA synthesis in porcine aortic smooth muscle cells in culture," Experimental Cell Research 200:358-360 (1992).

A. Jager, et al., "Oligonucleotide - alkylphosphoramidates: Synthesis and binding to polynucleotides," Biochemistry 27:7237-7246 (1988).

J.W. Jaroszewski, "Concerning antisense inhibition of the multiple drug resistance gene," Cancer Communications 2(8):287-294 (1990).

A. Jawien, et al., "Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in

a rat model of balloon angioplasty," J. Clin. Invest. 89:507-511 (1992).

N. Koyama, et al., "Different functions of the platelet-derived growth factor-alpha and -beta receptors for the migration and proliferation of cultured baboon smooth muscle cells," Circulation Research 75(4):682-691 (1994).

M. Kozak, "Influences of mRNA secondary structure on initiation by eukaryotic ribosomes," Proc. Natl. Acad. Sci. USA 83:2850-2854 (1986).

R. Langer, et al., "Controlled release and magnetically modulated release systems for macromolecules," Methods in Enzymology 112:399-423 (1985).

K.-W. Lau and U. Sigwart, "Restenosis-an accelerated arteriopathy: pathophysiology, preventive strategies and research horizons," In Molecular Interventions and Local Drug Delivery, R.E. Edelman and R.J. Levy, W.B. Saunders Company, Cambridge, UK, pp. 1-28 (1995).

J.M.E. Leiter, et al., "Inhibition of influenza virus replication by phosphorthioate oligodeoxynucleotides," Proc. Natl. Acad. Sci. USA 87:3430-3434 (1990).

S.A. Liebhaber, et al., "Intramolecular duplexes in eucaryotic mRNA suppress translation in a position-dependent manner," J. Cell. Biochem. 15D:CD007 (Abstract).

V. Lindner and A. Reidy, "Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against fibroblast growth factor," Proc. Natl. Acad. Sci. USA 88:3739-3743 (1991).

S.L. Loke, et al., "Characterization of oligonucleotide transport into living cells, Proc. Natl. Acad. Sci. USA 86:3474-3478 (1989).

M.W. Majesky, et al., "PDGF ligand and receptor gene expression during repair of arterial injury," The Journal of Cell Biology 111:2149-2158 (1990).

R. Morishita, et al., "Single intraluminal delivery of antisence cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia," Proc. Natl. Acad. Sci. USA 90:8474-8478 (1993).

R. Morishita, et al., "Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides," J. Clin. Invest. 93:1458-1464 (1994).

J.B. Murray, et al., "A micro sustained release system for epidermal growth factor," In vitro 19:743-748 (1983).

E.G. Nabel, et al., "Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia *in vivo*," J. Clin. Invest. 91:1822-1829 (1993).

J. Nielsen, et al., "Synthesis and characterization of dinucleoside phosphorodithioates," Tetrahedron Letters 29(24):2911-2914 (1988).

N.E. Olson, et al., "Intimal smooth muscle cell proliferation after balloon catheter injury," American Journal of Pathology 140(5):1017-1023 (1992).

R.S Paules, et al., "Mouse Mos protooncogene product is present and functions during oogenesis," Proc. Natl. Acad. Sci. USA 86:5395-5399 (1989).

E.W. Raines, et al., "Platelet-derived growth factor," In Peptide Growth Factors and Their Receptors, I.M.B. Sporn and A.B. Robert, editors, Springer-Velag, New York, pp. 173-262 (1991).

W.D. Rhine, et al., "A new approach to achieve zero-order release kinetics from diffusion-controlled polymer matrix systems," In Controlled Release of Bioactive Materials," R. Baker, editor, Academic Press, New York, pp. 177-187 (1980).

R. Ross, "The smooth muscle cell," The Journal of Cell Biology 50:172-186 (1971).

P.S. Sarin, et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," Proc. Natl. Acad. Sci. USA 85:7448-7451 (1988).

S.M. Schwartz, et al., "The intima soil for artherosclerosis and restenosis," Circulation Research 77(3):445-465 (1995).

S.M. Schwartz, et al., "Replication of smooth muscle cells in vascular disease," Circulation Research 58(4):427-444 (1986).

J.-P. Shaw, et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," Nucleic Acids Research 19(4):747-750 (1991).

Y. Shi, et al., "Down regulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells," Circulation 88:1190-1195 (1993).

Y. Shi, et al., "Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury," Circulation 90(2):944-951 (1994).

M. Simons, et al., "Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model," J. Clin. Invest. 93:2351-2356 (1994).

M. Simons and R.D. Rosenberg, "Antisense nonmuscle nyosin heavy chain and c-myb oligonucleotides suppress

smooth muscle cell proliferation *in vitro*," Circulation Research 70(4):835-843 (1992).

M. Simons, et al., "Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation *in vivo*," Nature 359:67-70 (1992).

E. Speir S.E. Epstein, "Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen," Circulation 86(2):538-547 (1992).

C.A. Stein, "Does antisense exist?" Nature Medicine 1(11):1119-1121 (1995).

B. Uznanski, et al., "Deoxyribonucleoside 3'-phosphordiamidites as substrates for solid supported synthesis of oligodeoxyribonucleotides and their phosphororhioate and DNA-triester analogues," Tetrahedron Letters 28:3401-3404 (1987).

R.W. Wagner and K. Nishikura, "Cell cycle expression of RNA duplex unwindase activity in mammalian cells," Molecular and Cellular Biology 8(2):770-777 (1988).

A.M. Wang, et al., "Molecular cloning of the complementary DNA for human tumor necrosis factor," Science 228:149-154 (1985).

E. Wickstrom, et al., "Complementary oligonucleotide probe of vasicular stomatitis virus matrix protein mRNA translation," Biophys. J. 49:15-17 (1986).

L.A. Yakubov, et al., "Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA 86:6454-6458 (1989).

P.C. Zamecnik, et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA," Proc. Natl. Acad. Sci. USA 83:4143-4146 (1986).

P.C. Zamecnik and M.L. Stephenson, "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," Proc. Natl. Acad. Sci. USA 75(1):280-284 (1978).

S. Banai, et al., "PGDF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth *in vitro* and reduces neointimal formation after balloon angioplasty in swine," Circulation 97:1960-1969 (1998).

G. Bilder, et al., "Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A," Circulation 99:3292-3299 (1999).

C.E. Hart, et al., "PDGFβ receptor blockade inhibits intimal hyperplasia in the baboon," Circulation 99:564-569 (1999).

S. Tanizawa, et al., "Expression of platelet derived growth factor B chain and β receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study," Heart 75:549-556 (1996).

No fee is believed necessary to enter this statement. However, if a fee is necessary, please charge Deposit Account 17-0055.

Respectfully submitted,

Martin G. Sirois, et al.

November 8, 2001

By: 

Jean C. Baker
Reg. No. 35,433
Quarles & Brady LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202-4497
(414) 277-5709